SCHEMBL972354

SCHEMBL972354

CCc1c[c]ncc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2251105 0.82
SCHEMBL294392 0.79 TDP1 (0.39)
SCHEMBL294765 0.78 CYP2C19 (0.36)
SCHEMBL4932430 0.78
SCHEMBL10526885 0.77 HRH3 (0.45)
SCHEMBL1981573 0.77 TDP1 (0.46)
SCHEMBL6950370 0.77 ALDH1A1 (0.32)
SCHEMBL27029414 0.76
SCHEMBL1244340 0.76
SCHEMBL1515146 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114591422-A Cystine knot scaffold platform 豪夫迈·罗氏有限公司 2022-06-07 CN claimed
US-9868740-B2 Pyrimidinone compounds which are HNE inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2018-01-16 US claimed
EP-3154977-A1 NOVEL COMPOUNDS Chiesi Farmaceutici S.p.A. (IT) 2017-04-19 EP claimed
US-20170101413-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2017-04-13 US claimed
CN-106459054-A Novel compounds 奇斯药制品公司 2017-02-22 CN claimed
WO-2015188866-A1 NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-17 WO claimed
WO-2015057992-A1 BTK INHIBITORS FOR HEMATOPOIETIC MOBILIZATION IZUMI RAQUEL (US) 2015-04-23 WO claimed
CN-101312977-B Fused heterocyclic compounds useful as kinase modulators BRISTOL MYERS SQUIBB CO 2012-06-13 CN claimed
US-7626030-B2 Compounds and methods of use AMGEN INC. (US) 2009-12-01 US claimed
CN-101481359-A Cyclic protein tyrosine kinase inhibitors BRISTOL MYERS SQUIBB CO (US) 2009-07-15 CN claimed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 EP claimed
EP-1711495-A2 QUINOLINE, QUINAZOLINE, PYRIDINE AND PYRIMIDINE COUNDS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER AMGEN INC. (US) 2006-10-18 EP claimed
US-20050245547-A1 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma AMGEN INC. 2005-11-03 US claimed
WO-2005073224-A2 QUINOLINE QUINAZOLINE PYRIDINE AND PYRIMIDINE COUNDS AND THEIR USE IN THE TREATMENT OF INFLAMMATION ANGIOGENESIS AND CANCER AMGEN INC (US) 2005-08-11 WO claimed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 WO claimed
EP-1065206-B1 Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents PFIZER (US) 2002-10-09 EP claimed
EP-1133498-A2 AMINO-AND MERCURIO-SUBSTITUTED 4', 5'-DIHYDROPSORALENS AND THERAPEUTICAL USES THEREOF BUCKMAN LABORATORIES INTERNATIONAL, INC. (US) 2001-09-19 EP claimed
EP-1065206-A1 Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents PFIZER INC. (US) 2001-01-03 EP claimed
WO-2000031081-A2 AMINO- AND MERCURIO-SUBSTITUTED 4',5'-DIHYDROPSORALENS AND THERAPEUTICAL USES THEREOF BUCKMAN LABORATORIES INTERNATIONAL, INC. (US) 2000-06-02 WO claimed
WO-1999011633-A1 TRIAZINES WITH AN ADENOSINE ANTAGONISTIC EFFECT BOEHRINGER INGELHEIM PHARMA KG (DE) 1999-03-11 WO claimed